Endocrine Abstracts

IntroductionDiabetic nephropathy is the leading cause of end-stage-kidney disease (ESKD). Clinical practice guidelines recommend prescribing renin–angiotensin aldosterone system inhibitors (RAASi) to prevent diabetic nephropathy at any stage. We conducted this extensive meta-analysis to compare the effects of RAASi with placebo and other antihypertensives in adults with diabetes on binary and continuous renal outcomes to provide a comprehensive revi...